Nilotinib
Treatment for Chronic Myeloid Leukemia
Typical Dosage: 300 mg twice daily
Effectiveness
91%
Safety Score
58%
Clinical Trials
141
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg twice daily
Time to Effect
1-3 months for initial molecular response
Treatment Duration
Lifetime (or 5+ years for TFR attempts)
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$2,500
Side Effect Mgmt:$1,200
Total Annual:$133,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
10.8
Outcome-Based Costs
Cost per Responder
$171,410
Cost per Remission
$278,542
Comparison vs Imatinib (generic)
Cost Difference
+$122,950/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Nilotinib Outcomes
for Chronic Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+91%
Response Rate
+78%
Remission Rate
+48%
Common Side Effects
Cardiovascular events (QT prolongation, atherosclerosis)
+15%
Myelosuppression
+25%
Nausea/vomiting
+25%
Headache
+25%
Fatigue
+25%
Rash
+25%
Pancreatitis
+7%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
14 completed trials for Nilotinib in Chronic Myeloid Leukemia
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
NCT00980018COMPLETEDPHASE4
52 participants
INTERVENTIONAL
Fayetteville, United States +22 more
Started: Dec 1, 2009
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
NCT01316250COMPLETEDNA
13 participants
INTERVENTIONAL
Beirut, Lebanon
Started: Aug 1, 2010
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
NCT01804985COMPLETEDPHASE2
174 participants
INTERVENTIONAL
Liverpool, United Kingdom
Started: Dec 1, 2013
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT01274351COMPLETEDPHASE2
112 participants
INTERVENTIONAL
Eskişehir, Turkey (Türkiye) +12 more
Started: Jan 25, 2011
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
NCT05734053COMPLETED
222 participants
OBSERVATIONAL
Freudenstadt, Germany +76 more
Started: Jun 28, 2016
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial
NCT01368523COMPLETEDPHASE4
19 participants
INTERVENTIONAL
Gdansk, Poland +2 more
Started: Dec 1, 2008
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740COMPLETEDPHASE2
148 participants
INTERVENTIONAL
Houston, United States
Started: Jun 27, 2005
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
NCT03874858COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Bari, Italy +25 more
Started: Mar 22, 2019
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
NCT02001818COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Adelaide, Australia
Started: Apr 11, 2014
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
NCT05286528COMPLETED
1.48K participants
OBSERVATIONAL
Budapest, Hungary
Started: Nov 18, 2020
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
NCT01254188COMPLETEDPHASE3
421 participants
INTERVENTIONAL
Algiers, Algeria +99 more
Started: Apr 1, 2011
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
NCT00802841COMPLETEDPHASE3
191 participants
INTERVENTIONAL
Caba, Argentina +55 more
Started: May 1, 2009
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
NCT02546674COMPLETEDPHASE4
171 participants
INTERVENTIONAL
Mannheim, Germany +69 more
Started: Feb 18, 2016
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
NCT00760877COMPLETEDPHASE3
207 participants
INTERVENTIONAL
Caba, Argentina +29 more
Started: Jun 1, 2009
Showing 20 of 141 total trials